Search 

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

We are Simbec-Orion, who for almost five decades, have been providing clinical trial management services across a wide range of therapeutic indications and phases. The clinical research organisation with a flexible, specialist approach, we strive to become a trusted partner for our clients. Our passion as a CRO is rare diseases and oncology.

Sphere Fluidics is developing picodroplets and single cell analysis systems and services for therapeutic discovery.

Specialities
Biopharmaceutical, lab-on-a-chip, cells, antibodies, microfluidics, enzymes, cancer, biologics, biotechnology, pharmaceutical, life sciences, immunology, oncology, cell therapies, and stem cells

Stratagem's "Strategically Different" approach delivers:
• An out-sourced, total intellectual property management solution.
• An investible patent strategy and maximised value of intellectual property.
• Hands-on management of the creation, maintenance, defence, commercialization, and enforcement of IP rights.
• A proven strategic approach to securing freedom to commercialise and competitive advantage.
Services For BioPartner Members:
• Free 30-minute initial consultation for IP-related matters
• IP overview training sessions for entire companies or select groups e.g. managers or inventors
• Contributions towards presentations, panel discussions, and/or Q&A sessions.

Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facilities in Nottingham and Alderley Park, UK housing over 500 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.

Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org

ViaNautis swas spun out of UCL from the laboratories of Prof. Giueseppe Battaglia in 2018. 

Following a successful, oversubscribed late seed funding, the company now works from labs at the Babraham Research Campus. The company’s proprietary technology, PolyNaut® can be applied to both clinical and non clinical/ex vivo products.

ViaNautis works with pharma and biotech partners for innovation and problem solving in neurology, oncology and immune diseases. Our partners Abcam PLC market and develop non-clinical products.

Viramal is a Specialty Pharmaceutical Company developing a portfolio of therapies in the fields of male & female sexual health focussing on the utilisation and application of sex steroid hormones.

Viramal’s patent protected technology platform facilitates superior drug delivery both transdermally and to sensitive female reproductive areas with an outstanding safety profile. Similar to cosmetic creams, Viramal’s products have excellent patient acceptability, and unlike competitors does not require alcohol for API solubility or absorption enhancement. All of the Company’s products benefit from the avoidance of the First Hepatic Pass, and the safety/ metabolite concerns that result other marketed products, particularly in Menopausal Hormone Therapy.